Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Prostate Cancer

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 32 articles:
HTML format



Single Articles


    October 2023
  1. APARICIO A
    Biochemical Recurrence in Prostate Cancer - Tilting the Scale.
    N Engl J Med. 2023;389:1522-1523.
    PubMed    


  2. FREEDLAND SJ, de Almeida Luz M, De Giorgi U, Gleave M, et al
    Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2023;389:1453-1465.
    PubMed     Abstract available


  3. NADAMUNI M, D'Amico AV, Donovan JL, Hamdy FC, et al
    Decision Making in Prostate Cancer.
    N Engl J Med. 2023;389:1335-1338.
    PubMed    


    July 2023
  4. PINSKY PF, Parnes H
    Screening for Prostate Cancer. Reply.
    N Engl J Med. 2023;389:94.
    PubMed    


  5. PRESTI J JR, Alexeeff S, Avins AL
    Screening for Prostate Cancer.
    N Engl J Med. 2023;389:93-94.
    PubMed    


  6. INAMURA K
    Screening for Prostate Cancer.
    N Engl J Med. 2023;389:93.
    PubMed    


  7. HOOVER J, Butterfass C, Ponder A
    Screening for Prostate Cancer.
    N Engl J Med. 2023;389:92-93.
    PubMed    


  8. HAMDY FC, Donovan JL
    Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer. Reply.
    N Engl J Med. 2023;389:92.
    PubMed    


  9. DAVIS MJ, Stephens A, Abdollah F
    Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer.
    N Engl J Med. 2023;389:90-92.
    PubMed    


    June 2023

  10. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    N Engl J Med. 2023;388:2208.
    PubMed    


    April 2023

  11. Waiting on Prostate Cancer.
    N Engl J Med. 2023;388:e54.
    PubMed    


  12. PINSKY PF, Parnes H
    Screening for Prostate Cancer.
    N Engl J Med. 2023;388:1405-1414.
    PubMed    


    March 2023
  13. SARTOR O
    Localized Prostate Cancer - Then and Now.
    N Engl J Med. 2023 Mar 11. doi: 10.1056/NEJMe2300807.
    PubMed    


  14. HAMDY FC, Donovan JL, Lane JA, Metcalfe C, et al
    Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    N Engl J Med. 2023 Mar 11. doi: 10.1056/NEJMoa2214122.
    PubMed     Abstract available


    February 2023
  15. FIZAZI K, Piulats JM, Reaume MN, Ostler P, et al
    Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
    N Engl J Med. 2023 Feb 16. doi: 10.1056/NEJMoa2214676.
    PubMed     Abstract available


  16. GAGLIANO-JUCA T, Hirsch MS, McGregor BA, Basaria S, et al
    Failure of Androgen-Deprivation Therapy Due to Ectopic hCG Secretion.
    N Engl J Med. 2023;388:660-662.
    PubMed    


    December 2022
  17. GULATI R
    Reducing Prostate Cancer Overdiagnosis.
    N Engl J Med. 2022;387:2187-2188.
    PubMed    


  18. HUGOSSON J, Mansson M, Wallstrom J, Axcrona U, et al
    Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
    N Engl J Med. 2022;387:2126-2137.
    PubMed     Abstract available


    September 2022

  19. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
    N Engl J Med. 2022;387:860.
    PubMed    


    June 2022
  20. SMITH MR
    Darolutamide in Metastatic Prostate Cancer. Reply.
    N Engl J Med. 2022;386:2345.
    PubMed    


  21. BOWLING GC, Dimitrakoff JD
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    PubMed    


  22. TURCO F, Tucci M, Buttigliero C
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    PubMed    


    February 2022
  23. SMITH MR, Hussain M, Saad F, Fizazi K, et al
    Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
    N Engl J Med. 2022 Feb 17. doi: 10.1056/NEJMoa2119115.
    PubMed     Abstract available


    December 2021
  24. SARTOR O, Morris MJ, Kraus BJ
    Lutetium-177-PSMA-617 for Prostate Cancer. Reply.
    N Engl J Med. 2021;385:2495-2496.
    PubMed    


  25. DALLA VOLTA A, Grisanti S, Berruti A
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2495.
    PubMed    


  26. KASHIHARA T, Kashihara K
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2494-2495.
    PubMed    


  27. HINDIE E
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2494.
    PubMed    


    November 2021
  28. EKLUND M, Discacciati A, Nordstrom T
    MRI-Targeted Biopsy in Prostate Cancer Screening. Reply.
    N Engl J Med. 2021;385:2110-2111.
    PubMed    


  29. YOSHIDA S, Fujii Y
    MRI-Targeted Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021;385:2110.
    PubMed    


  30. AL HUSSEIN AL AWAMLH B, Spratt DE, Shoag JE
    MRI-Targeted Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021;385:2109-2110.
    PubMed    


    July 2021
  31. EKLUND M, Jaderling F, Discacciati A, Bergman M, et al
    MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852.
    PubMed     Abstract available


    June 2021
  32. SARTOR O, de Bono J, Chi KN, Fizazi K, et al
    Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMoa2107322.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.